Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase NA 2Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 13Other hematologic neoplasm 12Plasma cell 7Dermatologic 6Myeloid 5Genitourinary 4Breast 4Head & Neck 3Thoracic 2Sarcoma 2Gynecologic 1Gastrointestinal 1Classical hematology 1CNS 1

Conditions

Liver Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 778Fluorouracil 637Capecitabine 573Gemcitabine 478Leucovorin 458Irinotecan 444Bevacizumab 443Cisplatin 337Radiotherapy 282Cetuximab 251Paclitaxel 180S 1 (combination) 175pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 130apatinib 130130-nm albumin-bound paclitaxel 127Folfox protocol 120durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106Surgical Procedures, Operative 102regorafenib 101Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Flow Cytometry × Gastrointestinal × Clear all
NCT00410956 2024-12-10

Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
22 enrolled 12 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡